Investigating how neutrophils contribute to lung damage in early cystic fibrosis
Neutrophil hyperexocytosis and hypochlorous acid exposure in early cystic fibrosis lung disease
This study is looking at how certain immune cells called neutrophils can cause lung problems in people with cystic fibrosis, especially early on, and aims to find new ways to help improve lung health by understanding how these cells interact with lung tissue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10979143 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of neutrophils in causing inflammation and damage in the lungs of patients with cystic fibrosis (CF). It aims to explore how neutrophils release harmful substances that can lead to airway injury, particularly in the early stages of the disease. By studying the mechanisms behind neutrophil activity and its effects on airway epithelial cells, the research seeks to identify potential new treatments that could improve lung health in CF patients. The approach involves analyzing the interactions between neutrophils and airway cells to uncover how inflammation develops and progresses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis, particularly those in the early stages of the disease.
Not a fit: Patients with cystic fibrosis who are in advanced stages of the disease or those who do not exhibit neutrophil-dominated inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively reduce lung inflammation and improve the quality of life for cystic fibrosis patients.
How similar studies have performed: Previous research has indicated that targeting neutrophil activity can be beneficial in managing airway inflammation in cystic fibrosis, suggesting that this approach has potential for success.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Chandler, Joshua D — Emory University
- Study coordinator: Chandler, Joshua D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.